National Center on Minority Health and Health Disparities; Notice of Closed Meeting, 32634 [05-11095]
Download as PDF
<![CDATA[
32634
Federal Register / Vol. 70, No. 106 / Friday, June 3, 2005 / Notices
2003 (DHHS Reference No. E–314–2002/
0–US–01); PCT Application No. PCT/
US04/06703 filed 05 Mar 2004, which
published as WO 2004/081179 A2 on 10
Feb 2005 (DHHS Reference No. E–314–
2002/0–PCT–02); Licensing Contact:
Jesse S. Kindra; (301) 435–5559;
kindraj@mail.nih.gov.
This invention relates to the discovery
that tristetraprolin (TTP) can promote
the poly(A)RNase (PARN) mediated
deadenylation of polyadenylated
substrates containing AU-rich elements
(AREs). As one aspect of the invention,
the inventors have developed a cell free
system that may be used for the
purposes of assessing the effects of the
various system components or their
derivatives (i.e. AREs, PARN, or TTP)
on the deadenylation process or the
effects of various test agents on the
deadenylation process. Aspects of this
work have been published as follows:
Lai et al., 2003, Tristetraprolin and Its
Family Members Can Promote the CellFree Deadenylation of AU-Rich
Element-Containing mRNAs by Poly(A)
Ribonuclease, MCB 23(11):3798–3812.
This technology is available for
licensing on an exclusive or a nonexclusive basis.
In addition to licensing, the
technology is available for further
development through collaborative
research opportunities with the
inventors.
Tristetraprolin (TTP) Knockout Mice
Perry Blackshear et al (NIEHS).
DHHS Reference No. B–015–1999/0—
Research Material.
Licensing Contact: Michelle A. Booden;
301/451–7337;
boodenm@mail.nih.gov.
National Institutes of Health
researchers have developed knockout
mice that do not express Tristetraprolin
(TTP). TTP is an AU-rich element (ARE)
binding protein and the prototype of a
family of CCCH zinc finger proteins.
AREs were identified as conserved
sequences found in the 3’ untranslated
region (3’ UTR) of a variety of
transiently expressed genes including
early respsonse genes, proto-oncogenes,
and other growth regulatory genes.
AREs function as instability sequences
that target ARE-containing transcripts
for rapid mRNA decay. TTP functions
by binding directly to the ARE sequence
contained in the TNF-alpha mRNA,
which destabilizes and mediates rapid
decay of the TNF-alpha mRNA. More
recent studies demonstrate TTP’s ability
to downregulate IL–2 gene expression.
TTP knockout mice appear normal at
birth but soon develop inflammatory
arthritis, dermatitis, cachexia,
autoimmunity, and myeloid
VerDate jul<14>2003
18:03 Jun 02, 2005
Jkt 205001
hyperplasia. Almost all aspects of these
phenotypes can be prevented with
repeated injections of antibodies to
TNF. Moreover, macrophages isolated
from these mice exhibit increased
production of TNF-alpha and increased
amounts of TNF-alpha mRNA.
This transgenic mouse model will be
valuable in advancing our
understanding of the mechanisms
controlling mRNA turnover in immune
homeostasis as well as autoimmune
diseases. This model will also permit
the development of screening assays to
elucidate the functions and binding
partners for other members of the CCCH
zinc finger family as well as compounds
capable of inhibiting aberrant TNFalpha and IL–2 biosynthesis. Lastly, this
model will advance understanding of
the pathogenetic role for IL–2 and/or
TNF in various autoimmune and
inflammatory diseases. The mice will be
made available on a non-exclusive basis
under a Biological Materials License
Agreement.
Background scientific detail may be
found in Immunol. 2005 Jan 15;
174(2):953–61; Arthritis Res Ther. 2004;
6(6):248–64; and Science. 1998 Aug 14;
281(5379):1001–5.
Dated: May 23, 2005.
Steven M. Ferguson,
Director, Division of Technology Development
and Transfer, Office of Technology Transfer,
National Institutes of Health.
[FR Doc. 05–11096 Filed 6–2–05; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Center on Minority Health and
Health Disparities; Notice of Closed
Meeting
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. Appendix 2), notice
is hereby given of the following
meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Center on
Minority Health and Health Disparities
PO 00000
Frm 00071
Fmt 4703
Sfmt 4703
Special Emphasis Panel, NCMHD
Endowment.
Date: June 27–28, 2005.
Time: 3 p.m. to 5 p.m.
Agenda: To review and evaluate grant
applications.
Place: Bethesda Marriott, 5151 Pooks Hill
Road, Bethesda, MD 20814.
Contact Person: Merlyn M. Rodrigues, PhD,
MD, Director, Office of Extramural Activities,
National Center On Minority Health and
Health Disparities, National Institutes of
Health, 6707 Democracy Blvd. Suite 800,
Bethesda, MD 20894, (301) 402–1366,
rodrigm1@mail.nih.gov.
Dated: May 25, 2005.
LaVerne Y. Stringfield,
Director, Office of Federal Advisory
Committee Policy.
[FR Doc. 05–11095 Filed 6–2–05; 8:45 am]
BILLING CODE 4140–01–M
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Institute of Diabetes and
Digestive and Kidney Disorders;
Notice of Closed Meeting
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. Appendix 2) notice
is hereby given of the following
meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The purpose of this
meeting is to evaluate requests for
preclinical development resources for
potential new therapeutics for Type 1
diabetes. The outcome of the evaluation
will be a decision whether NIDDK
should support the request and make
available contract resources for
development of the potential
therapeutic to improve the treatment or
prevent the development of Type 1
diabetes and its complications. The
research proposals and the discussions
could disclose confidential trade secrets
or commercial property such as
patentable material, and personal
information concerning individuals
associated with the proposed research
projects, the disclosure of which would
constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Institute of
Diabetes and Digestive and Kidney Disorders
Special Emphasis Panel; Type 1 Diabetes—
Rapid Access to Intervention Development.
Date: June 21, 2005.
Time: 3 p.m.–4 p.m.
Agenda: To evaluate requests for
preclinical development resources for
E:\FR\FM\03JNN1.SGM
03JNN1
]]>Agencies
[Federal Register Volume 70, Number 106 (Friday, June 3, 2005)]
[Notices]
[Page 32634]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 05-110]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
National Center on Minority Health and Health Disparities; Notice
of Closed Meeting
Pursuant to section 10(d) of the Federal Advisory Committee Act, as
amended (5 U.S.C. Appendix 2), notice is hereby given of the following
meeting.
The meeting will be closed to the public in accordance with the
provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5
U.S.C., as amended. The grant applications and the discussions could
disclose confidential trade secrets or commercial property such as
patentable material, and personal information concerning individuals
associated with the grant applications, the disclosure of which would
constitute a clearly unwarranted invasion of personal privacy.
Name of Committee: National Center on Minority Health and Health
Disparities Special Emphasis Panel, NCMHD Endowment.
Date: June 27-28, 2005.
Time: 3 p.m. to 5 p.m.
Agenda: To review and evaluate grant applications.
Place: Bethesda Marriott, 5151 Pooks Hill Road, Bethesda, MD
20814.
Contact Person: Merlyn M. Rodrigues, PhD, MD, Director, Office
of Extramural Activities, National Center On Minority Health and
Health Disparities, National Institutes of Health, 6707 Democracy
Blvd. Suite 800, Bethesda, MD 20894, (301) 402-1366,
rodrigm1@mail.nih.gov.
Dated: May 25, 2005.
LaVerne Y. Stringfield,
Director, Office of Federal Advisory Committee Policy.
[FR Doc. 05-11095 Filed 6-2-05; 8:45 am]
BILLING CODE 4140-01-M
